Clinical trial · no report yet · Phase 3
MoonRISe-3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- NCT06919965 ↗
- Recruiting
- Janssen Research & Development, LLC
- 10 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- TAR-210; Mitomycin C; Gemcitabine
- Arms
- Group A: TAR-210 · Experimental
- Group B: Mitomycin C (MMC) or Gemcitabine · Active comparator
- Enrollment
- 220 (estimated)
- Primary outcomes
- Disease-free Survival (DFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Sep 10, 2025
- Primary completion
- Apr 6, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06919965 · updated Sep 28, 2026